<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30454008</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>20</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1479-5876</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>16</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>19</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of translational medicine</Title>                <ISOAbbreviation>J Transl Med</ISOAbbreviation>            </Journal>            <ArticleTitle>Possibility of avoiding axillary lymph node dissection by immune microenvironment monitoring in preoperative chemotherapy for breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>318</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-018-1692-3</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The diagnosis of metastasis by sentinel lymph node biopsy (SLNB) in early breast cancer surgery provides an accurate view of the state of metastases to the axillary lymph nodes, and it has now become the standard procedure. In the present study, whether omission of axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC) is possible by evaluation of tumor-infiltrating lymphocytes (TILs) before NAC in cases without metastasis on diagnostic imaging, but with metastasis on SLNB, was retrospectively investigated.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 91 patients with resectable, early-stage breast cancer, diagnosed as cT1-2, N0, M0, underwent SLNB and were treated with NAC. A semi-quantitative evaluation of lymphocytes infiltrating the peritumoral stroma as TILs in biopsy specimens of primary tumors prior to treatment was conducted.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In cases with a low number of TILs, estrogen receptor expression was significantly higher (p = 0.044), and human epidermal growth factor receptor 2 (HER2) expression was significantly lower than in other cases (p = 0.019). The number of TILs was significantly lower in cases in which the intrinsic subtype was hormone receptor-positive breast cancer (HRBC) (p = 0.044). Metastasis to axillary lymph nodes was significantly more common in HER2-negative cases and cases with a low number of TILs (p = 0.019, p = 0.005, respectively).</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Even if macrometastases are found on SLNB in cN0 patients, it appears that ALND could be avoided after NAC in cases with a good immune tumor microenvironment of the primary tumor.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Takada</LastName>                    <ForeName>Koji</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kashiwagi</LastName>                    <ForeName>Shinichiro</ForeName>                    <Initials>S</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0460-9599</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. spqv9ke9@view.ocn.ne.jp.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goto</LastName>                    <ForeName>Wataru</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Asano</LastName>                    <ForeName>Yuka</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Takahashi</LastName>                    <ForeName>Katsuyuki</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fujita</LastName>                    <ForeName>Hisakazu</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Scientific and Linguistic Fundamentals of Nursing, Osaka City University Graduate School of Nursing, 1-5-17 Asahi-machi, Abeno-ku, Osaka, 545-0051, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Takashima</LastName>                    <ForeName>Tsutomu</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tomita</LastName>                    <ForeName>Shuhei</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hirakawa</LastName>                    <ForeName>Kosei</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ohira</LastName>                    <ForeName>Masaichi</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>25461992</GrantID>                    <Agency>Japan Society for the Promotion of Science</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>26461957</GrantID>                    <Agency>Japan Society for the Promotion of Science</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>17K10559</GrantID>                    <Agency>Japan Society for the Promotion of Science</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>19</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Transl Med</MedlineTA>            <NlmUniqueID>101190741</NlmUniqueID>            <ISSNLinking>1479-5876</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Microenvironment</Keyword>            <Keyword MajorTopicYN="N">Neoadjuvant chemotherapy</Keyword>            <Keyword MajorTopicYN="N">Sentinel lymph node biopsy</Keyword>            <Keyword MajorTopicYN="N">Tumor-infiltrating lymphocytes</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>11</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30454008</ArticleId>            <ArticleId IdType="doi">10.1186/s12967-018-1692-3</ArticleId>            <ArticleId IdType="pii">10.1186/s12967-018-1692-3</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>